Organigram Global (NASDAQ:OGI) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Organigram Global (NASDAQ:OGI) issued its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04), Zacks reports. Organigram Global had a negative return on equity of 13.41% and a negative net margin of 9.22%.

Here are the key takeaways from Organigram Global’s conference call:

• Record financial performance: Q3 net revenue rose 49% year over year to CAD 105.8 million, while adjusted EBITDA reached a record CAD 13.4 million and adjusted gross margin expanded to 37%. Management expects fiscal 2026 revenue to exceed CAD 350 million, with margins and EBITDA meaningfully above fiscal 2025 levels.
• Sanity Group is scaling as planned: The German business contributed €24.5 million of revenue during OrganiGram’s ownership period, and international sales represented roughly 35% of consolidated revenue. Management expects Sanity’s revenue growth to continue, with operating expenses remaining relatively stable and creating further P&L leverage.
• Canadian product recovery is gaining traction: New vape hardware and higher-potency products helped improve vape share in June, while infused pre-rolls returned to growth. Flower share increased to 12.5% year over year, and beverages and concentrates also posted strong gains as the company reduces its SKU count and focuses on higher-performing products.
• International supply and margin opportunities remain significant: OrganiGram is improving Canadian flower pass rates, adding suppliers, and pursuing EU GMP-compliant remediation pathways to meet tight German demand. EU GMP certification could meaningfully improve margins by reducing reliance on European processing, although no approval timeline was provided.
• Cash flow remains a near-term concern: Free cash flow was negative CAD 3.9 million in Q3, and management expects negative free cash flow for fiscal 2026 because of working-capital investments supporting the larger Sanity-led business. Cash and cash equivalents were CAD 11.7 million at quarter end, although total liquidity including debt facilities was CAD 49.2 million.

Organigram Global Stock Up 11.0%

OGI opened at $1.17 on Tuesday. The stock’s 50 day moving average price is $0.98 and its two-hundred day moving average price is $1.24. The firm has a market capitalization of $164.24 million, a P/E ratio of -8.96 and a beta of 1.46. Organigram Global has a 12-month low of $0.85 and a 12-month high of $2.24.

Wall Street Analyst Weigh In

A number of analysts have weighed in on OGI shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Organigram Global in a research report on Tuesday, June 9th. Wall Street Zen lowered Organigram Global from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Organigram Global

Hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Organigram Global in the fourth quarter worth $1,260,000. Two Sigma Investments LP acquired a new position in Organigram Global during the 3rd quarter valued at $907,000. Renaissance Technologies LLC raised its stake in Organigram Global by 43.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after purchasing an additional 423,900 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Organigram Global by 82.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock valued at $784,000 after purchasing an additional 210,391 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Organigram Global in the 4th quarter valued at $280,000. 34.63% of the stock is owned by institutional investors.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.